Stock Analyst Notes
| Browse Analyst Notes by Company : A B C D E F G H I J K L M N O P Q R S T U V W X Y Z All |
Endo Pharmaceuticals ENDP reported steady third-quarter results that were in line with our expectations, and we are keeping our fair value estimate in place. Total revenue increased 14% from the year-ago quarter to $361 million. The bulk of sales in the firm's pain-management segment came from its flagship pain patch Lidoderm, which brought in $193 million for the quarter and remained flat on a year-over-year basis. While constituting a smaller percentage of overall sales, the Opana and Voltaren Gel franchises generated strong growth of 42% and 100% for the quarter, respectively. We believe these ancillary pain products will continue to represent important growth opportunities, especially as the firm nears Lidoderm's loss of marketing exclusivity. Revenue from the newly acquired oncology and endocrinology business added $14 million to revenue this quarter, and sales of generic products remained flat.
.is(':checked'))MM_swapImgRestore(); else MM_swapImage('Checkbox1','','http://im.mstar.com/Im/Mbr/Form_PremCheckbox_Checked.gif',1);void($('#emailMe').attr('checked', !$('#emailMe').is(':checked')))){kind=small}